Aptevo Therapeutics Price to Free Cash Flow Ratio 2014-2021 | APVO

Historical price to free cash flow ratio values for Aptevo Therapeutics (APVO) since 2014. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Aptevo Therapeutics Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-25 5.79 0.00
2021-09-30 15.44 $-5.26 0.00
2021-06-30 22.43 $-6.68 0.00
2021-03-31 30.52 $-7.00 0.00
2020-12-31 36.65 $-8.67 0.00
2020-09-30 7.60 $-10.15 0.00
2020-06-30 8.35 $-10.19 0.00
2020-03-31 3.70 $-9.10 0.00
2019-12-31 9.16 $-14.58 0.00
2019-09-30 8.24 $-16.39 0.00
2019-06-30 12.41 $-21.09 0.00
2019-03-31 12.60 $-30.42 0.00
2018-12-31 17.78 $-32.62 0.00
2018-09-30 71.12 $-38.43 0.00
2018-06-30 69.86 $-32.22 0.00
2018-03-31 45.78 $-30.66 0.00
2017-12-31 59.36 $-28.21 0.00
2017-09-30 32.06 $-22.62 0.00
2017-06-30 28.98 $-44.05 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.027B $0.004B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.972B 8.78
Bio-Rad Laboratories (BIO.B) United States $16.992B 34.48
QIAGEN (QGEN) Netherlands $11.128B 18.85
Biohaven Pharmaceutical Holding (BHVN) United States $7.780B 0.00
Emergent Biosolutions (EBS) United States $2.486B 8.94
Arcus Biosciences (RCUS) United States $2.230B 0.00
Myovant Sciences (MYOV) United Kingdom $1.231B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.064B 0.00
Zymeworks (ZYME) Canada $0.466B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Ambrx Biopharma (AMAM) United States $0.193B 0.00
Enzo Biochem (ENZ) United States $0.153B 19.75